CINECA IRIS Institutional Research Information System

SCHIRRIPA, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.441
AS - Asia 1.035
EU - Europa 773
SA - Sud America 252
AF - Africa 72
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.576
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.372
SG - Singapore 342
CN - Cina 272
BR - Brasile 216
HK - Hong Kong 214
IT - Italia 187
DE - Germania 110
VN - Vietnam 100
SE - Svezia 97
BG - Bulgaria 79
GB - Regno Unito 70
RU - Federazione Russa 52
CA - Canada 50
AT - Austria 42
FR - Francia 41
TR - Turchia 29
CI - Costa d'Avorio 23
FI - Finlandia 23
NG - Nigeria 20
AR - Argentina 18
IN - India 17
SN - Senegal 17
NL - Olanda 15
MX - Messico 12
BD - Bangladesh 10
ID - Indonesia 9
JP - Giappone 9
PL - Polonia 9
EC - Ecuador 8
UA - Ucraina 8
CZ - Repubblica Ceca 7
PK - Pakistan 6
LT - Lituania 5
SA - Arabia Saudita 5
TW - Taiwan 5
AL - Albania 4
BE - Belgio 4
CH - Svizzera 4
ES - Italia 4
DO - Repubblica Dominicana 3
EG - Egitto 3
PE - Perù 3
VE - Venezuela 3
ZA - Sudafrica 3
BJ - Benin 2
EE - Estonia 2
IL - Israele 2
IQ - Iraq 2
MA - Marocco 2
MY - Malesia 2
RO - Romania 2
UZ - Uzbekistan 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
GD - Grenada 1
HR - Croazia 1
HU - Ungheria 1
IE - Irlanda 1
IM - Isola di Man 1
IR - Iran 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
KR - Corea 1
LK - Sri Lanka 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PY - Paraguay 1
QA - Qatar 1
RE - Reunion 1
RS - Serbia 1
TH - Thailandia 1
TM - Turkmenistan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.576
Salva come PNG Salva come JPEG
Città #
Ashburn 273
Woodbridge 271
Fairfield 222
Hong Kong 209
Singapore 207
Santa Clara 198
Houston 164
Chandler 115
Seattle 109
Dallas 93
Cambridge 85
Shanghai 84
Ann Arbor 80
Sofia 79
Wilmington 70
New York 69
Beijing 68
Boardman 47
Vienna 38
Princeton 35
São Paulo 33
Lawrence 31
Ottawa 29
Des Moines 27
Los Angeles 27
Abidjan 23
Medford 23
Ho Chi Minh City 22
Florence 21
Bremen 20
Lagos 20
London 18
Dakar 17
Düsseldorf 17
Istanbul 17
Dearborn 16
Lancaster 16
Redondo Beach 16
Buffalo 15
Council Bluffs 15
Serra 14
Hanoi 13
Munich 13
Nanjing 13
San Diego 13
Pisa 11
Marseille 9
Milan 9
Phoenix 9
Warsaw 9
Dong Ket 8
Frankfurt am Main 8
Montreal 8
Redwood City 8
Tokyo 8
Curitiba 7
Nuremberg 7
Rio de Janeiro 7
Rome 7
Shenyang 7
Toronto 7
Turku 7
Brasília 6
Brooklyn 6
Kunming 6
Lauterbourg 6
Mexico City 6
Positano 6
Seacroft 6
Ankara 5
Atlanta 5
Denver 5
Ogden 5
Brussels 4
Bắc Ninh 4
Carrara 4
Changsha 4
Detroit 4
Fuzhou 4
Guangzhou 4
Hebei 4
Lusciano 4
Quito 4
Verona 4
Boston 3
Chicago 3
Cislago 3
Hefei 3
Helsinki 3
Hải Dương 3
Izmir 3
Johannesburg 3
Napoli 3
Orem 3
Portsmouth 3
Prague 3
San Francisco 3
San Vito Chietino 3
Sete Lagoas 3
Stockholm 3
Totale 3.295
Salva come PNG Salva come JPEG
Nome #
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 195
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 171
TAS-102 for the treatment of metastatic colorectal cancer 170
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 162
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 157
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 149
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 148
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 and TRIBE trials 147
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer 144
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 142
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 141
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 140
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 136
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 135
Clinical significance of tlr1 i602s polymorphism for patients with metastatic colorectal cancer treated with folfiri plus bevacizumab 132
null 129
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 129
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 120
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 119
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 110
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 110
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial 107
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 105
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 102
null 98
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 97
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 96
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 89
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 89
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 86
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 86
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 85
null 85
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer 83
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer. 80
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 75
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 66
First-line chemotherapy for mCRC-a review and evidence-based algorithm 66
null 65
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 61
null 48
Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab' 27
Totale 4.682
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.528
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.528
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021154 0 0 0 0 0 6 18 17 37 19 18 39
2021/2022303 5 14 3 7 57 54 9 7 16 26 10 95
2022/2023439 40 66 31 56 47 55 4 20 84 4 31 1
2023/2024241 19 16 37 4 42 37 24 6 4 2 21 29
2024/20251.236 5 61 71 44 160 169 81 46 105 175 102 217
2025/2026901 108 197 173 208 173 42 0 0 0 0 0 0
Totale 4.682